Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1159)	7/25/2003 1:18:04 PM
From: keokalani'nui	Respond to of 1834

From today’s PFE CC: by: DewDiligence 07/25/03 12:03 pm Msg: 5667 of 5667 “We have a lot of enthusiasm for this one [Indiplon]” --Hank McKinnel, CEO In the Q&A, PFE was asked about the Indiplon NDA timing in Europe, but PFE declined to comment. PFE noted that filing requirements for insomnia medicines are slightly different in the EU than in the U.S., but no details were given. (Outside the U.S., PFE has full control over clinical development.)

To: Icebrg who wrote (1159)	7/28/2003 8:34:07 AM
From: Icebrg	Respond to of 1834

Neurocrine Biosciences Announces Initiation of Phase II Clinical Trial With NBI-5788 for Multiple Sclerosis Monday July 28, 8:01 am ET SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX - News) announced today the initiation of a Phase II clinical trial with NBI-5788, an altered peptide ligand (APL) for the treatment of relapsing multiple sclerosis (MS). This multicenter, randomized, double blind, placebo-controlled trial will evaluate the safety and tolerability of 5 mg injections of NBI-5788 administered in five weekly doses followed by eight monthly doses for a total of nine months. Additionally, it will investigate the disease-modifying effects of NBI-5788 using a summary change score for total gadolinium (Gd)-enhancing cranial Magnetic Resonance Imaging (MRI) lesions after nine months of treatment. The trial, led by principal investigator Dr. Jack Antel, Professor of Neurology at McGill University in Montreal, is being conducted in approximately 150 male and female patients with MS aged 18 to 55 years in approximately 25 study centers across the United States and Canada. Scientists of the Immune Tolerance Network (ITN), an international research consortium that aims to accelerate the clinical development of immune tolerance therapies for use in transplantation, autoimmune diseases and allergy and asthma, are partnering with Neurocrine to further investigate the immunological mechanisms of action of NBI-5788 in these patients with MS. The ITN is sponsored by the National Institute of Allergy and Infectious Diseases, with additional funds provided by the National Institute of Diabetes and Digestive and Kidney Diseases and the Juvenile Diabetes Research Foundation. A prior Phase II study of NBI-5788 involving doses of 5 mg, 20 mg and 50 mg suggested clinical improvement in patients who were administered the lowest dose (5 mg). Based on the results from this earlier study, this new trial will further define the efficacy and safety of NBI-5788 at the 5 mg dose compared with placebo. "We are extremely encouraged by the continued involvement of lead investigators from our previous clinical program with NBI-5788 along with the new support of the National Institutes of Health (NIH) for developing this novel class of compound as a specific immune therapy for MS," said Gary Lyons, President and Chief Executive Officer of Neurocrine Biosciences. "The possibility of a less frequently administered therapy may hold significant advantages for patients enduring this chronic illness. Results from this second Phase II trial are expected in 2005."